Utility of metabolic stability screening: comparison of in vitro and in vivo clearance

1. The ability of hepatic microsomal metabolic stability assessments to predict in vivo clearance in rat has been retrospectively evaluated for 1163 compounds from 48 programmes of chemistry. Using a simple binary classification system, the in vivo clearances of ~64% of the compounds were correctly classified. 2. About 24% of compounds were metabolically stable yet had clearance greater than half of liver blood flow in vivo. This might be expected as microsomes only contain a limited number of fully functioning drug-metabolizing enzymes and cannot be expected to account for extrahepatic or non-metabolic clearance processes. 3. About 13% of compounds had in vivo clearances of less than half liver blood flow despite being classified as metabolically unstable. Despite overcoming metabolic instability, these compounds had other undesirable properties and were generally more highly bound to plasma proteins, had smaller volumes of distribution (and shorter halflives despite their clearance) and were more inhibitory against the major human cytochrome P450s. 4. Taking plasma protein binding into consideration reduced the proportion of misclassified low-clearance compounds but did not improve the overall success appreciably. Somewhat surprisingly, human microsomes were nearly as effective as rat microsomes at classifying rat in vivo clearance.

[1]  J. Bloomer,et al.  Lauric acid as a model substrate for the simultaneous determination of cytochrome P450 2E1 and 4A in hepatic microsomes. , 1994, Chemical research in toxicology.

[2]  T Lavé,et al.  Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques. , 1999, Journal of medicinal chemistry.

[3]  B. W. Penman,et al.  Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. , 1997, Analytical biochemistry.

[4]  J. Houston,et al.  Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans. , 1999, British journal of clinical pharmacology.

[5]  C H Nightingale,et al.  Basic principles of pharmacokinetics. , 1987, Clinics in laboratory medicine.

[6]  J B Houston,et al.  Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices. , 1997, Drug metabolism reviews.

[7]  Rodrigues Ad,et al.  Preclinical drug metabolism in the age of high-throughput screening: an industrial perspective. , 1997 .

[8]  R. Obach,et al.  Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[9]  J B Houston,et al.  In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[10]  Grant R. Wilkinson,et al.  A physiological approach to hepatic drug clearance , 1975 .

[11]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.